S100A8 and myelofibrosis: Interestingly, upregulation of S100a8 and a9 appears to be a general feature of proinflammatory changes in (pre-)malignant disease, and in a murine JAK2V16F model of myelofibrosis, the S100A8/9 inhibitor tasquinimod, ameliorates development of malignancies, suggesting that targeting this arm of proinflammatory molecules are tangible targets in malignancies such as MPN (Leimkühler et al., 2021).